Thursday, March 11, 2010 Last update: 2:30 AM

State-by-State AND City-by-City FreshNews.com Delivers Company Tech News

Sepracor Inc.

print this company - email to a friend - join our eNewsletter

News articles for Sepracor Inc.:

Friday, February 19, 2010

Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America

Posted at 02/19/2010 - 12:00am

Wednesday, January 27, 2010

FDA Extends PDUFA Action Date for STEDESA™ New Drug Application

Posted at 01/27/2010 - 5:00pm

Wednesday, December 2, 2009

Sepracor to Present New STEDESA™ Clinical Data at American Epilepsy Society Annual Meeting

Posted at 12/02/2009 - 6:05am

Monday, October 26, 2009

Sepracor Announces Tender Offer for 0% Series B Convertible Senior Subordinated Notes Due 2010

Posted at 10/26/2009 - 10:47am

Tuesday, October 20, 2009

Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.

Posted at 10/20/2009 - 12:15pm
Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Completion of Subsequent Offering Period and Exercise of Top-Up Option

Posted at 10/20/2009 - 4:00am

Thursday, September 24, 2009

Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period

Posted at 09/24/2009 - 3:00am

Wednesday, September 2, 2009

Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion

Posted at 09/02/2009 - 8:37pm

Monday, August 10, 2009

Sepracor Announces New Drug Submission (NDS) to Health Canada for STEDESA™ as Adjunctive Treatment for Epilepsy

Posted at 08/10/2009 - 3:00am

Friday, July 24, 2009

Sepracor Inc. Reports Strong Second Quarter 2009 Operating Results and Increases Financial Guidance for 2009

Posted at 07/24/2009 - 3:00am

Monday, July 20, 2009

Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2009 Operating Results

Posted at 07/20/2009 - 3:00am

Wednesday, July 1, 2009

Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA® Pediatrics

Posted at 07/01/2009 - 1:00pm

Monday, June 1, 2009

Sepracor’s STEDESA™ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA

Posted at 06/01/2009 - 3:00am

Thursday, April 30, 2009

Sepracor Reports Strong First Quarter 2009 Operating Results and Reiterates Financial Guidance for 2009

Posted at 04/30/2009 - 3:00am

Monday, April 27, 2009

Sepracor Reports Preliminary Phase III Study Results for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis

Posted at 04/27/2009 - 3:00am

Thursday, April 23, 2009

Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2009 Operating Results

Posted at 04/23/2009 - 3:00am

Tuesday, March 31, 2009

Sepracor Announces Submission of STEDESA(™) New Drug Application to FDA for Adjunctive Treatment of Epilepsy

Posted at 03/31/2009 - 3:00am

Friday, March 20, 2009

Sepracor Files Patent Infringement Lawsuit Against Eszopiclone ANDA Filers

Posted at 03/20/2009 - 1:15pm

Tuesday, March 17, 2009

Sepracor Completes Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024

Posted at 03/17/2009 - 5:05am

Tuesday, March 10, 2009

Sepracor Announces Final Settlement of XOPENEX® Inhalation Solution Patent Infringement Litigation with Barr Laboratories, Inc. and Grant of Non-Exclusive License to Barr and Teva Pharmaceuticals USA,

Posted at 03/10/2009 - 12:45pm

Add new comment

Biotech/Biomedical/Health

Science/ Research

FreshMoney Deals - Mergers/Acquisitions/Funding/

Tech People on the Move

Financials/Webcasts

Massachusetts

United States